Aldeyra Therapeutics (DE:137)
NASDAQ:137
137 Stock Chart & Stats
€1.52
-€0.11(-2.29%)
At close: 4:00 PM EST
€1.52
-€0.11(-2.29%)
Day’s Range― - ―
52-Week Range€1.05 - €5.05
Previous CloseN/A
Volume0.00
Average Volume (3M)97.00
Market Cap
€85.30M
Enterprise Value-€49.49T
Total Cash (Recent Filing)€65.00M
Total Debt (Recent Filing)€15.51M
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Jul 31, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding60,321,068
10 Day Avg. Volume241
30 Day Avg. Volume97
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio-9.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.73Price Target Upside211.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.36
Revenue Forecast (FY)€18.63M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsSeveral trials reported treatment effects and pooled analyses could build a compelling efficacy case for the drug in reducing signs and symptoms of dry eye disease.
Controlled Chamber StudyA chamber study conducted in highly controlled conditions demonstrated meaningful benefit on ocular discomfort, helping address variability seen in conventional dry eye trials.
Partnership And Commercialization RightsAn outstanding option agreement with AbbVie grants US development and commercialization rights, creating a clear pathway for strategic partnership or acquisition that could accelerate market access.
Bears Say
Competitive Market DynamicsA crowded dry eye treatment market with multiple prescription drugs and many over-the-counter options could restrict market penetration even if regulatory approval is obtained.
Complete Response LetterThe FDA issued a Complete Response Letter indicating the application lacks substantial evidence from adequate and well-controlled studies to show the drug works as represented, posing a significant approval hurdle.
Regulatory Inconsistency ConcernsFDA reviewers flagged inconsistent study results that weaken the reliability and meaningfulness of positive findings across trials, raising regulatory uncertainty.
Aldeyra Therapeutics News
137 FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was €1.05 and its highest was €5.05 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is €85.30M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is Jul 31, 2026 which is in 52 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Apr 30, 2026. The company reported -€0.049 earnings per share for the quarter, missing the consensus estimate of -€0.045 by -€0.004.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 60,321,068 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -€0.049 in its last earnings report, missing expectations of -€0.045. Following the earnings report the stock price went up 1.575%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in DE:137
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aldeyra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.73 (211.08% Upside)
€4.73 (211.08% Upside)
Blogger Sentiment
Bullish
DE:137 Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €450.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.46%
12-Months-Change
Fundamentals
Return on Equity
>-0.01%
Trailing 12-Months
Asset Growth
-28.66%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company focused on the discovery and commercialization of therapeutic agents for ocular and systemic immune-mediated disorders. The firm's primary investigational compound is reproxalap, a reactive aldehyde species (RASP) modulator, currently in Phase III clinical trials for addressing dry eye disease and allergic conjunctivitis. Additionally, Aldeyra is advancing ADX-629, an innovative, first-in-class RASP modulator designed for oral administration, which is undergoing Phase II studies for conditions such as psoriasis, asthma, and COVID-19. Another pipeline asset, ADX-2191, a dihydrofolate reductase inhibitor, is in Phase 3 for the prevention of proliferative vitreoretinopathy and in Phase II trials for treating retinitis pigmentosa and primary vitreoretinal lymphoma. The company also holds a license agreement with Madrigal Pharmaceuticals, Inc. for the development of ADX-1612, a compound that inhibits the protein chaperome to tackle inflammatory diseases. Originally incorporated in 2004 as Aldexa Therapeutics, Inc., the company officially adopted the name Aldeyra Therapeutics, Inc. in March 2014 and is headquartered in Lexington, Massachusetts.
137 Stock 12 Month Forecast
Average Price Target
€4.73
▲(211.08% Upside)
Technical Analysis
Omeros
―
Galectin Therapeutics
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Options Prices
Currently, No data available
---